var data={"title":"Raxibacumab (United States: Availability limited to CDC distribution from strategic national stockpile in consultation with local health department) : Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Raxibacumab (United States:&nbsp;Availability limited to&nbsp;CDC&nbsp;distribution from strategic national stockpile in consultation with local health department) : Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/532190?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=raxibacumab-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information\" class=\"drug drug_general\">see &quot;Raxibacumab (United States:&nbsp;Availability limited to&nbsp;CDC&nbsp;distribution from strategic national stockpile in consultation with local health department) : Drug information&quot;</a> and <a href=\"topic.htm?path=raxibacumab-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-patient-drug-information\" class=\"drug drug_patient\">see &quot;Raxibacumab (United States:&nbsp;Availability limited to&nbsp;CDC&nbsp;distribution from strategic national stockpile in consultation with local health department) : Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26334773\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Monoclonal Antibody</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26334787\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Administer diphenhydramine (oral or IV depending on the proximity to start of raxibacumab infusion) &le;1 hour prior to administration of raxibacumab to reduce the risk of infusion reactions. Must be administered in combination with antimicrobial therapy. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anthrax, prophylaxis or treatment:</b> IV:  80 mg/kg as a single dose </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26334777\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=raxibacumab-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information\" class=\"drug drug_general\">see &quot;Raxibacumab (United States:&nbsp;Availability limited to&nbsp;CDC&nbsp;distribution from strategic national stockpile in consultation with local health department) : Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Administer diphenhydramine (oral or IV depending on the proximity to start of raxibacumab infusion) &le;1 hour prior to administration of raxibacumab to reduce the risk of infusion reactions. Must be administered in combination with antimicrobial therapy. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Anthrax, prophylaxis or treatment:</b> Infants, Children, and Adolescents: IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&le;15 kg: 80 mg/kg as a single dose </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;15 kg to 50 kg: 60 mg/kg as a single dose </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;50 kg: 40 mg/kg as a single dose </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Anthrax, prophylaxis or treatment:</b> IV: 40 mg/kg as a single dose </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in manufacturer's labeling; however, dosage adjustment unlikely as clearance is nonrenal. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustment provided in manufacturer's labeling (has not been studied). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16243478\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, solution: 50 mg/mL (34 mL) [contains polysorbate 80, sucrose 10 mg/mL]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16234640\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16234633\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Raxibacumab is not available for general public use. All supplies are currently owned by the federal government for inclusion in the Strategic National Stockpile and for use by the U.S. military. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26334779\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Must be diluted prior to administration. Premedicate with diphenhydramine &le;1 hour prior to raxibacumab infusion. Administer entire dose over 2 hours and 15 minutes; administration rate should be slower over the first 20 minutes to monitor for adverse reactions; slow or interrupt infusion if adverse reactions (including infusion-related reactions) occur. Administer as follows: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Body weight: &le;1 kg: Infuse at 0.5 mL/hour for 20 minutes; increase rate to 3.5 mL/hour for the remaining infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Body weight 1.1 to 2 kg: Infuse at 1 mL/hour for 20 minutes; increase rate to 7 mL/hour for the remaining infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Body weight 2.1 to 3 kg: Infuse at 1.2 mL/hour for 20 minutes; increase rate to 10 mL/hour for the remaining infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Body weight 3.1 to 4.9 kg: Infuse at 1.5 mL/hour for 20 minutes; increase rate to 12 mL/hour for the remaining infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Body weight 5 to 10 kg: Infuse at 3 mL/hour for 20 minutes; increase rate to 25 mL/hour for the remaining infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Body weight 11 to 30 kg: Infuse at 6 mL/hour for 20 minutes; increase rate to 50 mL/hour for the remaining infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Body weight &ge;31 kg: Infuse at 15 mL/hour for 20 minutes; increase rate to 125 mL/hour for the remaining infusion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16235219\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Unused vials should be stored at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze.  Protect from light. Diluted solutions are stable for 8 hours at room temperature.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26334774\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of inhalational anthrax following exposure to <i>Bacillus anthracis</i> in combination with appropriate antimicrobial therapy; prophylaxis of inhalational anthrax when alternative therapies are unavailable or not appropriate (All indications: FDA approved in all ages)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16235180\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Pain</p>\n    <p style=\"text-indent:0em;\">Dermatologic: Pruritus, skin rash (infusion-related; more common without diphenhydramine premedication)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anemia, back pain, drowsiness, fatigue, flushing, hypertension, increased creatine phosphokinase, increased serum amylase, insomnia, leukopenia, lymphadenopathy, muscle spasm, pain (at infusion site), palpitations, peripheral edema, prolonged prothrombin time, vasodepressor syncope, vertigo</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16234682\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16234683\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Infusion-related reactions (eg, rash, urticaria, pruritus) have been reported.  Premedication with diphenhydramine is recommended to reduce the risk. The administration rate is slowed over the first 20 minutes to monitor for adverse reactions; decrease the infusion rate or stop the infusion if adverse reactions (including infusion-related reactions) occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens).  Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Anthrax prophylaxis and treatment: Raxibacumab is not an antimicrobial agent; use should always be in combination with appropriate antimicrobial therapy.  Raxibacumab does not cross the blood brain barrier and is not appropriate for the prevention or treatment of meningitis due to anthrax infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Efficacy: The efficacy of raxibacumab in humans is presumptive and based solely on efficacy studies in animals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16369099\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16369097\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=98260&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16234656\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16234660\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. In general, guidelines for the prophylaxis and treatment of inhalational anthrax following exposure to <i>Bacillus anthracis</i> in pregnant and postpartum women are the same as nonpregnant adults (Meaney-Delman 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26334788\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Infusion-related adverse effects (eg, rash, urticaria, pruritus)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16235221\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Raxibacumab is a recombinant human IgG1 lambda monoclonal antibody which binds and neutralizes free protective antigen (PA) component of <i>Bacillus anthracis</i> toxin; as a result, PA-mediated delivery of lethal toxin and edema toxin via the anthrax toxin receptor (ATR) into host cells of anthrax-infected individuals is inhibited.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16235223\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 0.07 L/kg (Migone 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Terminal: 20.44 &plusmn; 6.46  days (Migone 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Nonrenal (Migone 2009)</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raxibacumab-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-pediatric-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raxibacumab-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-pediatric-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raxibacumab-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-pediatric-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n     Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mazumdar S, &ldquo;Raxibacumab,&rdquo; <i>MAbs</i>, 2009, 1(6):531-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raxibacumab-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-pediatric-drug-information/abstract-text/20068396/pubmed\" target=\"_blank\" id=\"20068396\">20068396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Migone TS, Subramanian GM, Zhong J, et al, &ldquo;Raxibacumab for the Treatment of Inhalational Anthrax,&rdquo; <i>N Engl J Med</i>, 2009, 361(12):135-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raxibacumab-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-pediatric-drug-information/abstract-text/19587338/pubmed\" target=\"_blank\" id=\"19587338\">19587338</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raxibacumab [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 98260 Version 18.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F26334773\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F26334787\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F26334777\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F16243478\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F16234640\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F16234633\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F26334779\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F16235219\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F26334774\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F16235180\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F16234682\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F16234683\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F16369099\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F16369097\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F16234656\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F16234660\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F26334788\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F16235221\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F16235223\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/98260|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=raxibacumab-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information\" class=\"drug drug_general\">Raxibacumab (United States:&nbsp;Availability limited to&nbsp;CDC&nbsp;distribution from strategic national stockpile in consultation with local health department) : Drug information</a></li><li><a href=\"topic.htm?path=raxibacumab-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-patient-drug-information\" class=\"drug drug_patient\">Raxibacumab (United States:&nbsp;Availability limited to&nbsp;CDC&nbsp;distribution from strategic national stockpile in consultation with local health department) : Patient drug information</a></li></ul></div></div>","javascript":null}